Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00642837
Other study ID # CR014803
Secondary ID
Status Completed
Phase Phase 4
First received March 21, 2008
Last updated April 24, 2014
Start date September 2007
Est. completion date May 2008

Study information

Verified date April 2014
Source Janssen Korea, Ltd., Korea
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Observational

Clinical Trial Summary

The objective of this observational study is to assess improvement of quality of life in the patients who are administered Tramadol 37.5mg/Acetaminophen 325mg tablets for 10~14 weeks according to the investigator's discretion in clinical practice.


Description:

Recently the concerns about the Health-Related Quality of Life (HRQOL) have been increasing especially in chronic diseases. Rheumatic disease is a chronic disease, which can result in a functional disability and impaired HRQOL. Because of this chronic pain, patients with rheumatic disease have lower scores on HRQOL than general population. A several studies have indicated Ultracet as an add-on treatment to nonsteroidal antiinflammatory drugs(NSAIDs) for osteoarthritis(OA) pain, fibromyalgia pain and chronic low back pain significantly improved HRQOL, compared with placebo. We will use the KEQ-5D (a Korean version of the EQ-5D which is a health related quality of life questionnaire) to assess HRQOL. The KEQ-5D has been shown to be effectively sensitive in several rheumatic conditions. The study hypothesis is that the quality of life will be improved after Tramadol 37.5mg/Acetaminophen 325mg tablets administration in outpatients who need Tramadol 37.5mg/Acetaminophen 325mg tablets administration at the investigator's discretion. This is a multicenter, open-label, prospective, observational study to compare HRQOL using Korean version of EQ-5D before and after the treatment with Tramadol 37.5mg/Acetaminophen 325mg tablets and to assess the correlation among each measurement. Observational Study - No investigational drug administered


Recruitment information / eligibility

Status Completed
Enrollment 982
Est. completion date May 2008
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender Both
Age group 12 Years and older
Eligibility Inclusion Criteria:

- Patients with rheumatism who have moderate-to-severe pain

- Patients who have not been administered Ultracet or tramadol over the last one month

- Patients who have signed a consent form indicating that they understand the purpose of and procedures required for the study (For minors between 12 and 20 years old, the patients' legally acceptable representatives' signature is also required.)

Exclusion Criteria:

- Patients who have experienced failure of tramadol therapy or discontinued Tramadol because of adverse events

- Patients with impaired physical function or disease which may cause drug absorption anomaly, excess storage and metabolic or elimination disorder

- Patients who meet any of the prohibitions of tramadol or acetaminophen

- Hypersensitive to active ingredients of the study drug

- Addicted to drugs acting on central nervous system including alcohol, hypnotics, centrally acting analgesics, opiates and psychotropics, serious respiratory depression (the study drug may cause mild respiratory depression)

- Patients with head injury and brain lesion who have the risk of decreased meantal awareness

- Patients who are taking an MAO inhibitor or discontinued it no more than 2 weeks ago

- Patients with peptic ulcer and severe hematological anomaly

- Patients with severe hepatic impairment, renal impairment or cardiac dysfunction

- Patients with aspirin-induced asthma (asthmatic attacks induced by nonsteroidal anti-inflammatory drug)

- Patients with epilepsy which is not controlled by a drug

- Patients who are pregnant or of childbearing potential during the study

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
Tramadol/acetaminophen
Osteoarthritis, flexible dose depending on patients' pain relief
Tramadol/acetaminophen
Post surgical neurophatic pain, flexible dose depending on patients' pain relief
Tramadol/acetaminophen
Post traumatic neuropathic pain, flexible dose depending on patient pain relief
Tramadol/acetaminophen
Spinal Cord Injury, flexible dose depending on patients' pain relief
Tramadol/acetaminophen
Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
Tramadol/acetaminophen
Diabetic Neuropathy, flexible dose depending on patients' pain relief
Tramadol/acetaminophen
Post stroke pain, flexible dose depending on patients' pain relief
Tramadol/acetaminophen
Low back pain, flexible dose depending on patients' pain relief
Tramadol/acetaminophen
Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
Tramadol/acetaminophen
Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Janssen Korea, Ltd., Korea

Outcome

Type Measure Description Time frame Safety issue
Primary KEQ-5D: Korean Version of EQ-5D which assess the health related quality of life of patient baseline and week 12 No
Secondary Pain relief baseline & week 12 No
Secondary Pain intensity baseline & week 12 No
See also
  Status Clinical Trial Phase
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT04042792 - Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate
Recruiting NCT05554029 - Coronaphobia in Rheumatic Diseases N/A
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Completed NCT02694796 - Impact of Web and Smartphone-based Physical Activity Program on Physical Activity Level 12 Months After a Balneotherapy N/A
Completed NCT02256098 - RSA RCT: ATTUNEā„¢ TKA Versus PFC Sigma TKA N/A
Completed NCT02269254 - Persona Versus NexGen N/A
Active, not recruiting NCT04704544 - Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE) N/A
Completed NCT05026853 - Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice N/A
Active, not recruiting NCT04631965 - Healthcare Transition of Adolescents With Chronic Health Conditions
Recruiting NCT00024479 - Natural History of Rheumatic Diseases in Minority Communities
Completed NCT05031104 - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis N/A
Not yet recruiting NCT04567576 - Predictive Factors for COVID-19 in Rheumatology
Completed NCT02291471 - Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers Phase 1
Completed NCT01227694 - Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis Phase 1/Phase 2
Recruiting NCT01071447 - Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment N/A
Active, not recruiting NCT05618782 - Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee Phase 2
Active, not recruiting NCT05543642 - The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) Phase 4
Active, not recruiting NCT02694185 - Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications N/A
Completed NCT04685434 - Validity and Reliability of "Shriners Hospital Upper Extremity Evaluation" in Children With Rheumatic Disease